<?xml version="1.0" encoding="UTF-8"?>
<p>Proton pump inhibitors (PPIs) are drugs widely prescribed to reduce gastric acidity. Although they are considered globally safe, observational studies
 <sup>
  <xref rid="zoi190614r1" ref-type="bibr">1</xref>,
  <xref rid="zoi190614r2" ref-type="bibr">2</xref>,
  <xref rid="zoi190614r3" ref-type="bibr">3</xref>
 </sup> have reported significant adverse effects associated with their long-term use, such as osteoporotic-related fractures, vitamin B
 <sub>12</sub> deficiency, kidney disease, or infections, particularly pulmonary and digestive tract infections. Numerous studies
 <sup>
  <xref rid="zoi190614r4" ref-type="bibr">4</xref>,
  <xref rid="zoi190614r5" ref-type="bibr">5</xref>,
  <xref rid="zoi190614r6" ref-type="bibr">6</xref>,
  <xref rid="zoi190614r7" ref-type="bibr">7</xref>,
  <xref rid="zoi190614r8" ref-type="bibr">8</xref>
 </sup> have reported an association between PPI use and bacterial enteric infections, such as isolated and recurrent 
 <italic>Clostridium difficile</italic> infections. By reducing the secretion of hydrochloric acid produced by the stomach, PPIs may promote the growth of the gastrointestinal microflora, increase bacterial translocation, affect the gastrointestinal microbiome, and weaken the immune system.
 <sup>
  <xref rid="zoi190614r9" ref-type="bibr">9</xref>
 </sup>
</p>
